$20.36
-1.40-6.43%
At close: -
$20.36
0.000.00%
After Hours: Apr 4, 4:00 PM EDT
Comments
Loading...
Kiniksa Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:KNSA | Benzinga
Kiniksa Pharmaceuticals International PLC has a consensus price target of $36.43 based on the ratings of 7 analysts. The high is $40 issued by Citigroup on March 13, 2025. The low is $32 issued by Goldman Sachs on July 26, 2023. The 3 most-recent analyst ratings were released by Citigroup, JP Morgan, and Evercore ISI Group on March 13, 2025, November 5, 2024, and October 30, 2024, respectively. With an average price target of $38.33 between Citigroup, JP Morgan, and Evercore ISI Group, there's an implied 88.28% upside for Kiniksa Pharmaceuticals International PLC from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Citigroup
JP Morgan
Evercore ISI Group
Jefferies
Wedbush
1calculated from analyst ratings
Analyst Ratings for Kiniksa Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/13/2025 | Buy Now | 96.46% | Citigroup | Geoff Meacham61% | → $40 | Initiates | → Buy | Get Alert |
| 11/05/2024 | Buy Now | 96.46% | JP Morgan | Anupam Rama57% | $39 → $40 | Maintains | Overweight | Get Alert |
| 10/30/2024 | Buy Now | 71.91% | Evercore ISI Group | Liisa Bayko69% | $30 → $35 | Maintains | Outperform | Get Alert |
| 09/13/2024 | Buy Now | 96.46% | Jefferies | Roger Song30% | → $40 | Initiates | → Buy | Get Alert |
| 07/23/2024 | Buy Now | 66.99% | Wedbush | David Nierengarten60% | $30 → $34 | Maintains | Outperform | Get Alert |
| 05/03/2024 | Buy Now | 66.99% | Wells Fargo | Eva Fortea Verdejo19% | → $34 | Initiates | → Overweight | Get Alert |
| 05/01/2024 | Buy Now | 47.35% | JP Morgan | Anupam Rama57% | $26 → $30 | Maintains | Overweight | Get Alert |
| 04/24/2024 | Buy Now | 47.35% | Evercore ISI Group | Liisa Bayko69% | $25 → $30 | Maintains | Outperform | Get Alert |
| 01/02/2024 | Buy Now | 22.79% | Wedbush | David Nierengarten60% | $23 → $25 | Maintains | Outperform | Get Alert |
| 07/26/2023 | Buy Now | 57.17% | Goldman Sachs | Paul Choi58% | $22 → $32 | Maintains | Buy | Get Alert |
| 03/09/2023 | Buy Now | -1.77% | JP Morgan | Anupam Rama57% | $19 → $20 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Kiniksa Pharmaceuticals (KNSA) stock?
The latest price target for Kiniksa Pharmaceuticals (NASDAQ:KNSA) was reported by Citigroup on March 13, 2025. The analyst firm set a price target for $40.00 expecting KNSA to rise to within 12 months (a possible 96.46% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kiniksa Pharmaceuticals (KNSA)?
The latest analyst rating for Kiniksa Pharmaceuticals (NASDAQ:KNSA) was provided by Citigroup, and Kiniksa Pharmaceuticals initiated their buy rating.
When was the last upgrade for Kiniksa Pharmaceuticals (KNSA)?
There is no last upgrade for Kiniksa Pharmaceuticals
When was the last downgrade for Kiniksa Pharmaceuticals (KNSA)?
There is no last downgrade for Kiniksa Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Kiniksa Pharmaceuticals (KNSA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kiniksa Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kiniksa Pharmaceuticals was filed on March 13, 2025 so you should expect the next rating to be made available sometime around March 13, 2026.
Is the Analyst Rating Kiniksa Pharmaceuticals (KNSA) correct?
While ratings are subjective and will change, the latest Kiniksa Pharmaceuticals (KNSA) rating was a initiated with a price target of $0.00 to $40.00. The current price Kiniksa Pharmaceuticals (KNSA) is trading at is $20.36, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.